Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas

• Published in: Human pathology 2020-12, Vol.106, p.82-92
• Main Authors: Nozaki, Yui, Yamamoto, Hidetaka, Iwasaki, Takeshi, Sato, Masanobu, Jiromaru, Rina, Hongo, Takahiro, Yasumatsu, Ryuji, Oda, Yoshinao
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; ALK; Anaplastic Lymphoma Kinase - genetics; Anaplastic thyroid carcinoma; Antibodies; Biomarkers, Tumor - genetics; Female; Gene Rearrangement; Genetic Predisposition to Disease; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kinases; Male; Middle Aged; Mutation; NTRK; pan-Trk; Papillary thyroid carcinoma; Phenotype; Predictive Value of Tests; Protein-Tyrosine Kinases - genetics; Proto-Oncogene Proteins - genetics; Receptor, trkA - genetics; Receptor, trkC - genetics; Reproducibility of Results; ROS1; Thyroid cancer; Thyroid Cancer, Papillary - genetics; Thyroid Cancer, Papillary - pathology; Thyroid Carcinoma, Anaplastic - genetics; Thyroid Carcinoma, Anaplastic - pathology; Thyroid Neoplasms - genetics; Thyroid Neoplasms - pathology; Tumors; Young Adult
• ISSN: 0046-8177; 1532-8392
• DOI: 10.1016/j.humpath.2020.09.004

NTRK1/3, ALK, and ROS1 translocations have been reported in a minor subset of papillary thyroid carcinomas (PTCs). We aimed to elucidate the prevalence and clinicopathological characteristics of these gene rearrangements and the utility of immunohistochemistry (IHC) in PTC and anaplastic thyroid carcinoma (ATC). We screened nonradiation-exposed cases of 307 PTCs and 16 ATCs by IHC for pan-Trk, ALK, and ROS1, followed by fluorescence in situ hybridization (FISH). In the PTC group, IHC for pan-Trk, ALK, and ROS1 was positive in 18 cases (5.9%), 1 case (0.3%), and 12 cases (3.9%), respectively. Among the pan-Trk IHC–positive cases (n = 18), 2 cases (11.1%; 0.7% of all PTCs) had NTRK1 or NTRK3 gene rearrangement with conventional PTC histology. The ALK IHC–positive case (n = 1) was the follicular variant of PTC with consistent ALK gene rearrangement. ROS1 gene rearrangement was not detectable in the ROS1 IHC–positive PTCs (0/12) by FISH. Most (approximately 70%) of the pan-Trk or ROS1 IHC–positive/FISH–negative cases had BRAF gene mutation with conventional PTC morphology. In the ATC group, neither ALK nor ROS1 IHC was positive, whereas pan-Trk IHC was positive in 1 case (6.3%) in which NTRK1 gene rearrangement was confirmed by FISH. These results suggest that NTRK, ALK, and ROS1 rearrangements are rare molecular events in nonradiation-exposed Japanese patients with PTC and ATC. Although IHC is not an entirely specific surrogate for these abnormalities and does not serve as a stand-alone companion diagnosis, the combined use of IHC and molecular testing may be helpful for determining promising therapeutic strategies with tyrosine kinase inhibitors.